Lv41
606 积分 2024-05-09 加入
Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
26天前
已完结
Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
1个月前
已完结
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
1个月前
已完结
Inflammation and resolution in obesity
1个月前
已完结
Macrophage and T cell networks in adipose tissue
1个月前
已完结
Abstract 4139912: Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2
1个月前
已关闭
Abstract 4139912: Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2
1个月前
已完结
Abstract 16779: Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial
2个月前
已关闭
On the meta-analysis of response ratios for studies with correlated and multi-group designs
2个月前
已完结
皖公网安备34019202002308
